EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

European Journal of Cancer

Volumn 46, Issue 2, 2010, Pages 348-354

  Brandes, Alba A ^a   Stupp, Roger ^b   Hau, Peter ^c   Lacombe, Denis ^d   Gorlia, Thierry ^d   Tosoni, Alicia ^a   Mirimanoff, Renè O ^e   Kros, Johan M ^f   van den Bent, Martin J ^f  

^a MAGGIORE HOSPITAL   (Italy)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d EORTC DATA CENTER   (Belgium)

^e Department of Radiation Oncology ^*  (Switzerland)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Glioblastoma; Phase I; PTK ZK; Radiotherapy; Temozolomide

Indexed keywords

TEMOZOLOMIDE; VATALANIB;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; INFECTION; MALE; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS HEPATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHTHALAZINES; PYRIDINES; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 72449155176     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.029     Document Type: Article

References (11)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009)
3. Reardon DA, Friedman AH, Yung WK, et al. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). In: ASCO annual meeting; 2004. p. 1513.
4. Abdollahi A., Lipson K.E., Han X., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63 (2003) 3755-3763
5. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
6. Parthymou A., Kardamakis D., Pavlopoulos I., et al. Irradiated C6 glioma cells induce angiogenesis in vivo and activate endothelial cells in vitro. Int J Cancer 110 (2004) 807-814
7. Geng L., Donnelly E., McMahon G., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61 (2001) 2413-2419
8. Macdonald D.R., Cascino T.L., Schold Jr. S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990) 1277-1280
9. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
10. Cloughesy T., MD P., Wen P., et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). ASCO, J Clin Oncol (2008) 2010b
11. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787